JP2022513700A5 - - Google Patents

Info

Publication number
JP2022513700A5
JP2022513700A5 JP2021531492A JP2021531492A JP2022513700A5 JP 2022513700 A5 JP2022513700 A5 JP 2022513700A5 JP 2021531492 A JP2021531492 A JP 2021531492A JP 2021531492 A JP2021531492 A JP 2021531492A JP 2022513700 A5 JP2022513700 A5 JP 2022513700A5
Authority
JP
Japan
Prior art keywords
composition according
combination
formula
tumor
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021531492A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022513700A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2019/001342 external-priority patent/WO2020115556A1/en
Publication of JP2022513700A publication Critical patent/JP2022513700A/ja
Publication of JP2022513700A5 publication Critical patent/JP2022513700A5/ja
Pending legal-status Critical Current

Links

JP2021531492A 2018-12-03 2019-12-03 放射性免疫複合体とチェックポイント阻害剤の併用療法 Pending JP2022513700A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862774847P 2018-12-03 2018-12-03
US62/774,847 2018-12-03
PCT/IB2019/001342 WO2020115556A1 (en) 2018-12-03 2019-12-03 Radioimmunoconjugates and checkpoint inhibitor combination therapy

Publications (2)

Publication Number Publication Date
JP2022513700A JP2022513700A (ja) 2022-02-09
JP2022513700A5 true JP2022513700A5 (https=) 2023-10-25

Family

ID=70973593

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021531486A Pending JP2022511471A (ja) 2018-12-03 2019-12-03 放射性免疫複合体とｄｎａの損傷および修復阻害剤の併用療法
JP2021531492A Pending JP2022513700A (ja) 2018-12-03 2019-12-03 放射性免疫複合体とチェックポイント阻害剤の併用療法
JP2024193520A Pending JP2025013486A (ja) 2018-12-03 2024-11-05 放射性免疫複合体とｄｎａの損傷および修復阻害剤の併用療法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2021531486A Pending JP2022511471A (ja) 2018-12-03 2019-12-03 放射性免疫複合体とｄｎａの損傷および修復阻害剤の併用療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024193520A Pending JP2025013486A (ja) 2018-12-03 2024-11-05 放射性免疫複合体とｄｎａの損傷および修復阻害剤の併用療法

Country Status (18)

Country Link
US (5) US20220088231A1 (https=)
EP (2) EP3890790A4 (https=)
JP (3) JP2022511471A (https=)
KR (2) KR20210099073A (https=)
CN (4) CN117482261A (https=)
AU (2) AU2019394888A1 (https=)
BR (2) BR112021010799A2 (https=)
CA (2) CA3119915A1 (https=)
CL (2) CL2021001432A1 (https=)
EA (2) EA202191557A1 (https=)
IL (2) IL283598A (https=)
MA (2) MA54399A (https=)
MX (2) MX2021006408A (https=)
PE (2) PE20211286A1 (https=)
PH (2) PH12021551282A1 (https=)
SG (2) SG11202105112RA (https=)
WO (2) WO2020115556A1 (https=)
ZA (1) ZA202103429B (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020142583A1 (en) * 2019-01-04 2020-07-09 Actinium Pharmaceuticals, Inc. Methods for treating cancer using combinations of parp inhibitors and antibody radioconjugates
BR112021022237A2 (pt) 2019-05-10 2022-03-29 Janssen Biotech Inc Queladores macrocíclicos e métodos de uso dos mesmos
AU2021206233A1 (en) * 2020-01-10 2022-08-11 Fusion Pharmaceuticals Inc. Sustained immunotherapy
WO2021207086A1 (en) * 2020-04-06 2021-10-14 Fusion Pharmaceuticals Inc. Tem-1-targeted radioimmunoconjugates and uses thereof
US20220267450A1 (en) 2020-10-14 2022-08-25 Viridian Therapeutics, Inc. Compositions and methods for treatment of thyroid eye disease
US20250275946A1 (en) * 2021-02-02 2025-09-04 Unm Rainforest Innovations Combination therapy for the treatment of cancer
US11541134B1 (en) 2021-08-02 2023-01-03 Rayzebio, Inc. Stabilized compositions of radionuclides and uses thereof
EP4384219A4 (en) 2021-08-10 2025-06-18 Viridian Therapeutics, Inc. COMPOSITIONS, DOSAGES AND METHODS FOR THE TREATMENT OF THYROID EYE DISEASE
US20250339571A1 (en) * 2021-08-27 2025-11-06 Actinium Pharmaceuticals, Inc. Radioimmunoconjugates targeting phosphatidylserine for use in the treatment of cancer
AU2021466827A1 (en) * 2021-09-29 2024-04-11 Fusion Pharmaceuticals Inc. Egfrviii-targeted compounds and uses thereof
TW202325344A (zh) * 2021-11-02 2023-07-01 加拿大商融合製藥公司 治療癌症之方法
US20250177581A1 (en) * 2022-01-28 2025-06-05 Fusion Pharmaceuticals Inc. Ntsr1-targeted radiopharmaceuticals and dna damage response inhibitor combination therapy

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5053503A (en) * 1989-02-17 1991-10-01 Centocor Chelating agents
WO1992022324A1 (en) 1991-06-14 1992-12-23 Xoma Corporation Microbially-produced antibody fragments and their conjugates
BRPI9809391B8 (pt) 1997-04-14 2021-05-25 Amgen Res Munich Gmbh processo para a produção de um receptor de antígeno anti-humano, anticorpo humano e composição farmacêutica
US7736651B1 (en) * 2000-11-24 2010-06-15 Sloan-Kettering Institute For Cancer Research Alpha emitting constructs and uses thereof
EP1838736B1 (en) * 2005-01-05 2013-03-06 Biogen Idec MA Inc. Cripto binding molecules
AU2007245164A1 (en) * 2006-03-28 2007-11-08 Biogen Idec Ma Inc. Anti-IGF-IR antibodies and uses thereof
WO2011060233A1 (en) * 2009-11-11 2011-05-19 The Trustees Of The University Of Pennsylvania Anti-tem1 antibodies and uses thereof
ES2978177T3 (es) 2009-12-02 2024-09-06 Immunomedics Inc Combinación de radio inmunoterapia y conjugados anticuerpo-fármaco para mejorar la terapia contra el cáncer
GB201120779D0 (en) 2011-12-02 2012-01-11 Immodulon Therapeutics Ltd Cancer therapy
GB201403875D0 (en) * 2014-03-05 2014-04-16 Cantargia Ab Novel antibodies and uses thereof
PT3134127T (pt) * 2014-04-25 2020-04-09 Rinat Neuroscience Corp Conjugados de anticorpo-fármaco com alta carga de fármaco
US10092645B2 (en) 2014-06-17 2018-10-09 Medimmune Limited Methods of treatment with antagonists against PD-1 and PD-L1 in combination with radiation therapy
EP3280439A1 (en) * 2015-04-07 2018-02-14 INSERM - Institut National de la Santé et de la Recherche Médicale Anti-pd-l1 immunotoxin for use in therapy
US11149087B2 (en) * 2015-04-20 2021-10-19 Etubics Corporation Methods and compositions for combination immunotherapy
EP3285809B1 (en) * 2015-04-20 2019-09-11 eFFECTOR Therapeutics, Inc. Inhibitors of immune checkpoint modulators for use in treating cancer and infections
AU2016271138A1 (en) * 2015-05-29 2017-12-07 Merrimack Pharmaceuticals, Inc. Combination cancer therapies
MX2018008345A (es) * 2016-01-11 2018-12-06 Univ Leland Stanford Junior Proteínas quiméricas y métodos de inmunoterapia.
EP3202788A1 (en) 2016-02-05 2017-08-09 MediaPharma S.r.l. Endosialin-binding antibody
TWI910495B (zh) * 2016-05-13 2026-01-01 美商再生元醫藥公司 藉由投予pd-1抑制劑治療皮膚癌之方法
US11633506B2 (en) * 2016-07-18 2023-04-25 Wisconsin Alumni Research Foundation Using targeted radiotherapy (TRT) to drive anti-tumor immune response to immunotherapies
EP3496707A4 (en) 2016-08-09 2020-03-25 Angimmune, LLC Treatment of cancer using a combination of immunomodulation and check point inhibitors
WO2018038680A1 (en) * 2016-08-24 2018-03-01 Scinopharm Taiwan, Ltd. Processes for preparing olaparib
WO2018049474A1 (en) * 2016-09-16 2018-03-22 Bionomics Limited Antibody and checkpoint inhibitor combination therapy
US11273155B2 (en) * 2016-12-12 2022-03-15 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate and immune checkpoint inhibitor
WO2018153975A1 (en) * 2017-02-24 2018-08-30 Bayer As Combination therapy comprising a radiopharmaceutical and a dna-repair inhibitor
MA48861A (fr) * 2017-05-05 2020-04-01 Fusion Pharmaceuticals Inc Améliorations pharmacocinétiques de chélates bifonctionnels et leurs utilisations
US10093741B1 (en) * 2017-05-05 2018-10-09 Fusion Pharmaceuticals Inc. IGF-1R monoclonal antibodies and uses thereof
WO2018204872A2 (en) * 2017-05-05 2018-11-08 Fusion Pharmaceuticals Inc. Igf-1r monoclonal antibodies and uses thereof
AU2018331430A1 (en) * 2017-09-13 2020-03-19 Radimmune Therapeutics, Inc. Melanin antibodies and uses thereof
EP3713607A1 (en) * 2017-11-22 2020-09-30 Nordic Nanovector ASA Radioimmunoconjugates in combination with other drugs as treatment against nhl
US20220125960A1 (en) * 2019-02-21 2022-04-28 Bayer Aktiengesellschaft Combination of pd-1/pd-l1 inhibitors and targeted thorium conjugates

Similar Documents

Publication Publication Date Title
JP2022513700A5 (https=)
US20240335572A1 (en) Radiolabeled anti-pd-l1 antibodies for immuno-pet imaging
Bidkar et al. Actinium-225 targeted alpha particle therapy for prostate cancer
JP2020518674A5 (https=)
EP2914302B1 (en) Radiolabelled antibody and uses thereof
RU2019139434A (ru) Моноклональные антитела против igf-1r и их применение
JP2022511471A5 (https=)
CN112513639B (zh) 用于成像的组合物和方法
PL216208B1 (pl) Zastosowanie kompozycji leczniczej zawierającej niesprzężone i sprzężone przeciwciała w immunoterapii nowotworów złośliwych i choroby autoimmunizacyjnej
EP2497501B1 (en) Radionuclides for medical use
JP2020507571A (ja) 免疫ｐｅｔイメージングのための放射標識抗ｌａｇ３抗体
BRPI0607486B1 (pt) Anticorpo humanizado l243 contra hla-dr presente nas células hladr+,composição farmacêutica, kit e uso dos referidos anticorpos.
JP2020518673A5 (https=)
CN112533952B (zh) 治疗疾病或病况的组合物及其用途
CN114555132A (zh) 放射性金属标记抗体的制造方法
US20220378956A1 (en) Trivalent Radioisotope Bio-Targeted Radiopharmaceutical, Methods Of Preparation And Use
JP7836270B2 (ja) 抗ｄｏｔａ／抗腫瘍抗原二重特異性抗体による事前標的化放射免疫治療のためのｄｏｔａ－ハプテン組成物
TW201627286A (zh) 放射性醫藥複合物
Song et al. Bismuth-213 radioimmunotherapy with C595 anti–MUC1 monoclonal antibody in an ovarian cancer ascites model
CN117836011A (zh) 将生物制剂与多种螯合剂组合的方法和材料
US20240299601A1 (en) Radiolabeled anti-lag3 antibodies for immuno-pet imaging
WO2026037323A1 (zh) 放射性核素标记的靶向pd-l1小蛋白及其制备方法与应用
US20100189642A1 (en) Radionuclides for medical use
CN113795511A (zh) 抗pd-l1双抗体及其用途
JP2024521418A5 (https=)